bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. is holding a Special Meeting of Stockholders on November 20, 2026, to vote on several key proposals. These include approving the issuance of shares related to August and October 2026 warrants, authorizing the company to issue additional securities in non-public offerings up to a certain limit, and reducing the total number of authorized shares. The company's Board of Directors recommends a 'FOR' vote on all proposals.

bioAffinity Technologies, Inc. reported a net loss of $3.37 million for the second quarter of 2026 and $7.00 million for the first six months of 2026. The company's cash and cash equivalents significantly decreased to $2.43 million by June 30, 2026, leading management to conclude there is substantial doubt about its ability to continue as a going concern. The accumulated deficit reached $75.6 million, highlighting the need for additional capital to support future operations.

bioAffinity Technologies reported its second quarter 2026 financial results, with revenue increasing 19% year-over-year to $1.5 million and net loss narrowing to $3.4 million from $4.1 million. The company highlighted strong commercial momentum for its CyPath Lung diagnostic test, with test volume surging 216% compared to the prior year. Strategic milestones included progress in a longitudinal clinical trial, expansion of its pipeline to include diagnostics for asthma and COPD, and development of skin cancer therapeutics.

bioAffinity Technologies, Inc. received a notice from Nasdaq on July 30, 2026, indicating non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days. The company is not eligible for the standard 180-day compliance period due to a 1-for-30 reverse stock split effected on September 19, 2025. bioAffinity Technologies plans to appeal the determination to Nasdaq on August 6, 2026, which will temporarily halt the delisting process.

bioAffinity Technologies, Inc. announced the publication of a comprehensive clinical review and white paper authored by its Chief Medical Officer, Gordon H. Downie, MD, PhD. The paper presents a practical clinical framework for integrating CyPath® Lung into pulmonary nodule evaluation and cancer surveillance. It outlines specialty-specific approaches for pulmonology, primary care, and oncology practices, emphasizing the test's noninvasive nature and its ability to provide objective, real-time information from the lung microenvironment.

bioAffinity Technologies, Inc. announced a collaboration with Pictor, Inc. to develop and commercialize next-generation diagnostic tests for lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD). This partnership aims to integrate bioAffinity's expertise in flow cytometry with Pictor's targeted proteomic analysis platform to enhance laboratory efficiency, reduce costs, and provide more personalized treatment insights. The tests, building on bioAffinity's proprietary sputum analysis approach, are designed to help physicians match patients with more effective and targeted therapies, addressing a global therapeutics market projected to exceed $108 billion in 2026.

bioAffinity Technologies announced continued acceleration in commercial sales for its noninvasive lung cancer diagnostic, CyPath® Lung, with over 200% year-over-year growth in Q2 2026. Sales volume also increased more than 30% compared to the previous quarter, driven by a 155% rise in physician offices ordering the test. The company has now performed nearly 3,000 CyPath® Lung tests since its commercial launch and is expanding its clinical impact with new initiatives, including monitoring lung cancer survivors and developing diagnostics for asthma and COPD.

bioAffinity Technologies reported significant growth in its CyPath® Lung test, with unit sales in April increasing nearly 300% year-over-year and physician ordering sites up 69% from Q1 2025 to Q1 2026. The company announced a partnership with Philips and 4DMedical to enhance lung cancer screening for US veterans. Additionally, bioAffinity is advancing its pipeline with companion diagnostics for asthma/COPD and preclinical research for topical skin cancer treatments.

bioAffinity Technologies, Inc. completed a public offering, raising approximately $3.2 million in gross proceeds. The offering included 1,040,000 shares of common stock at $0.80 per share and pre-funded warrants to purchase up to 2,960,000 shares at $0.793 per warrant. The company intends to use the net proceeds for working capital and general corporate purposes. WallachBeth Capital LLC acted as the sole placement agent, receiving a 7.5% fee and $120,000 in expense reimbursement.

bioAffinity Technologies, Inc. has filed an amendment to its S-1 registration statement, primarily updating and incorporating various exhibits. These exhibits include forms of placement agency agreements, warrants, certificates of incorporation and bylaws, as well as numerous material agreements related to employment, consulting, and past financing activities. The amendment does not appear to introduce new financial results or significant business developments beyond the incorporation of these documents.